Clinical Trial Update: pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pTVG-HP DNA vaccine with or without the pTVG-AR DNA vaccine plus pembrolizumab in castration-resistant, metastatic prostate cancer; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• pTVG-AR DNA vaccine
• pTVG-HP DNA vaccine

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-05